The deal blocks the parties from renewing their claims or counterclaims, according to Judge Maryellen Noreika’s order dismissing the case Friday in the US District Court for the District of Delaware. GSK in November added a newly issued patent to allegations that Pfizer’s Abrysvo infringes six other patents for GSK’s Arexvy, the first vaccine for RSV—which stands for respiratory syncytial virus—approved in the US.
- GlaxoSmithKline Biologicals SA and GlaxoSmithKline LLC, subsidiaries of GSK, sued Pfizer in August 2023 seeking damages and injunctive relief for Abrysvo’s alleged infringement of four patents. Their November 2023 amended complaint added allegations involving two more patents.
- Arexvy had sales of £590 million ($754.02 million) in 2024, 1.88% of GSK’s revenue, according to data compiled by Bloomberg.
- Abrysvo had sales of $755 million in 2024, 1.19% of Pfizer’s revenue, Bloomberg data show.
Wilmer Cutler Pickering Hale & Dorr LLP and Richards, Layton & Finger PA represent GSK. White & Case LLP and Morris, Nichols, Arsht & Tunnell LLP represent Pfizer.
The case is GlaxoSmithKline Biologicals SA v. Pfizer Inc., D. Del., No. 23-cv-831, dismissed 4/4/25.
To contact the reporter on this story:
To contact the editor responsible for this story:
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.